Detailed Narrative
Q2 FY25 Operational Turnaround and Margin Expansion
Camlin Fine Sciences reported a robust operational performance in Q2 FY25, with revenue reaching ₹422 crores, a 6.9% increase quarter-on-quarter. Gross margins significantly improved to 48.2%, primarily driven by the strong showing of Aroma products. The company achieved a double-digit operational EBITDA margin of 10.2%, marking a substantial expansion of 305 basis points QoQ and 242 basis points YoY. This led to a positive profit before exceptional item📎s of ₹8.73 crores, a notable recovery from the ₹23.48 crores loss in the previous quarter.
Strategic Impairments and Business Restructuring
The quarter was marked by strategic decisions to impair non-performing assets, resulting in total exceptional item📎s of ₹151 crores. This included a ₹116 crores impairment for the diphenol facility in CFS Europe, which has been shut down since August 2023, and a ₹30 crores impairment for CFS Wanglong in China. These actions aim to streamline operations, reduce future losses, and re-focus resources. Management expects the cost bleed from the European diphenol facility to reduce from ₹15-16 crores per quarter to ₹1 crore per quarter within two quarters.
Aroma Business: Strong Growth and Anti-Dumping Tailwinds
The Aroma products segment demonstrated exceptional growth, with revenue soaring to ₹45 crores in Q2 FY25 from just ₹13 crores in the preceding quarter. The company is currently operating at 40% capacity utilization for vanillin and aims to increase this to 55% by the end of FY25 and 75% by FY26, eventually reaching 100% of its 6,000 capacity within the next year. Management anticipates further benefits from ongoing anti-dumping duties against Chinese manufacturers by the US and Europe, with final orders expected by May/June next year.
Blends Business: Consistent Performance and Future Targets
The Blends business continues to be a reliable growth engine, with management targeting a 20% annual growth rate for the next two years. The company projects Blends revenue to grow from ₹700-750 crores in FY24 to approximately ₹1,000 crores in FY25. In Europe, the blending turnover is currently around ₹100 crores annually, and the standalone Blends business maintains a healthy 14-15% EBITDA margin, which is expected to improve with the planned cost reductions.
Performance Chemicals: Value-Added Products and Capacity Utilization
The Performance Chemicals segment experienced muted growth due to pricing headwinds. However, the company is focusing on developing value-added products based on hydroquinone and catechol, which are expected to drive a 15-20% growth in the next financial year. Quarterly revenue for this segment is projected to increase from ₹50 crores to ₹60-62 crores. The Dahej facility is currently operating at 80% capacity, with plans to increase utilization as vanillin and other downstream diphenol products scale up.
Debt and Liquidity Challenges
Camlin Fine Sciences faces significant debt, with gross debt standing at approximately ₹750 crores and net debt at ₹650 crores. While the company acknowledges the high debt and plans annual repayments of around ₹35 crores, management stated there is 'no constructive plan to reduce it immediately.' To address the liquidity situation and working capital requirements, the company is actively working on launching a rights issue in the near future, signaling ongoing financial management efforts.